Buspirone
Buspirone (buspirone) is a small molecule pharmaceutical. Buspirone was first approved as Buspar on 1986-09-29. It is used to treat anxiety disorders, depressive disorder, and intellectual disability in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1A. In addition, it is known to target 5-hydroxytryptamine receptor 7.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Buspirone (discontinued: Buspar, Buspirone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Buspirone hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BUSPAR | Bristol Myers Squibb | N-018731 DISCN | 1986-09-29 | 4 products, RLD |
| BUSPAR | Bristol Myers Squibb | N-021190 DISCN | 2000-12-20 | 4 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| buspar | ANDA | 2016-05-25 |
| buspirone | ANDA | 2010-03-29 |
| buspirone hcl | ANDA | 2023-06-29 |
| buspirone hcl | ANDA | 2024-05-16 |
| buspirone hydrochloride | ANDA | 2024-11-06 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
70 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 2 | 2 | 2 | 4 | 10 |
| Depression | D003863 | — | F33.9 | — | 3 | 1 | 3 | — | 7 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 2 | — | 3 | 1 | 6 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 3 | — | 1 | 2 | 6 |
| Autistic disorder | D001321 | HP_0000717 | F84.0 | 1 | 4 | 1 | 1 | 1 | 6 |
| Wounds and injuries | D014947 | — | T14.8 | 2 | 2 | — | 2 | — | 5 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 2 | — | 1 | 1 | 4 |
| Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | — | 2 | — | 1 | 1 | 4 |
| Pervasive child development disorders | D002659 | EFO_0003756 | F84 | — | 2 | — | 1 | 1 | 4 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 3 | — | 1 | — | 4 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 1 | 1 | — | — | 3 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 2 | — | — | 2 |
| Dyskinesias | D020820 | HP_0002310 | G24 | 1 | — | 1 | — | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 2 | — | — | 2 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | 1 | — | — | 1 |
| Apnea | D001049 | HP_0002104 | R06.81 | — | — | 1 | — | — | 1 |
| Ischemic stroke | D000083242 | — | — | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | — | 4 | 5 | — | — | — | 7 |
| Cocaine-related disorders | D019970 | — | F14 | — | 2 | — | — | 1 | 3 |
| Hypokinesia | D018476 | — | — | — | 2 | — | — | — | 2 |
| Psychological sexual dysfunctions | D020018 | — | F52.0 | — | 2 | — | — | — | 2 |
| Substance withdrawal syndrome | D013375 | EFO_0005800 | — | 1 | 1 | — | — | — | 2 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | 1 | — | — | — | 2 |
| Hyperkinesis | D006948 | HP_0000752 | — | — | 1 | — | — | — | 1 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
| Gastroparesis | D018589 | EFO_1000948 | K31.84 | — | 1 | — | — | — | 1 |
| Paresis | D010291 | HP_0001269 | — | 1 | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 2 | — | — | — | — | 2 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Disease | D004194 | EFO_0000408 | R69 | 2 | — | — | — | — | 2 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Movement disorders | D009069 | HP_0100022 | — | 1 | — | — | — | — | 1 |
| Traumatic stress disorders | D040921 | — | — | 1 | — | — | — | — | 1 |
| Paralysis | D010243 | HP_0003470 | — | 1 | — | — | — | — | 1 |
| Chronic pain | D059350 | HP_0012532 | — | 1 | — | — | — | — | 1 |
| Psychological dependency | D003858 | — | — | 1 | — | — | — | — | 1 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Buspirone |
| INN | buspirone |
| Description | Buspirone is an azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position. It has a role as an anxiolytic drug, a sedative, a serotonergic agonist and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is an azaspiro compound, a member of pyrimidines, a N-arylpiperazine, a N-alkylpiperazine, a member of piperidones and an organic heteropolycyclic compound. It is a conjugate base of a buspirone(1+). |
| Classification | Small molecule |
| Drug class | anxiolytics (buspirone type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 36505-84-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL49 |
| ChEBI ID | 3223 |
| PubChem CID | 2477 |
| DrugBank | DB00490 |
| UNII ID | TK65WKS8HL (ChemIDplus, GSRS) |
Target
Agency Approved
HTR1A
HTR1A
Organism
Homo sapiens
Gene name
HTR1A
Gene synonyms
ADRB2RL1, ADRBRL1
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1A
Protein synonyms
5-HT1a receptor, 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled, G-21, guanine nucleotide-binding regulatory protein-coupled receptor, Serotonin receptor 1A
Uniprot ID
Mouse ortholog
Htr1a (15550)
5-hydroxytryptamine receptor 1A (Q8BGS4)
Alternate
HTR7
HTR7
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Buspirone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,377 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,511 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use